Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Show more

1050 Waltham Street, Lexington, MA, 02421, United States

Biotechnology
Healthcare

Market Cap

218.7M

52 Wk Range

$9.69 - $22.55

Previous Close

$10.95

Open

$10.96

Volume

157,507

Day Range

$10.80 - $11.09

Enterprise Value

-22.79M

Cash

257.6M

Avg Qtr Burn

-20.42M

Insider Ownership

3.96%

Institutional Own.

95.32%

Qtr Updated

06/30/26


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KER-050 (elritercept) Details
Transfusion-dependent lower-risk MDS

Phase 3

Data readout

KER-050 (elritercept) Details
Blood cancer, Cystic fibrosis, Lung disease, Myelofibrosis, Cancer

Phase 3

Initiation

KER-065 Details
Duchenne muscular dystrophy

Phase 2

Data readout

Phase 2

Initiation

Phase 2

Initiation

Phase 1

Update

KER-012 (cibotercept) Details
Pulmonary hypertension, Cardiovascular disease

Failed

Discontinued

KER-047 (ALK2 inhibitor) Details
Fibrodysplasia ossificans progressiva, Anemia

Failed

Discontinued

KER-047 (ALK2 inhibitor) Details
Myelodysplastic syndrome, Myelofibrosis

Failed

Discontinued